1. Scrip

GSK To Maintain Lead With Newly Approved Meningococcal Vaccine Penmenvy

 
• By Andrew McConaghie

Pfizer has been unable to take a big slice of the meningococcal vaccine market with Penbraya and now GSK looks set to consolidate its lead with its new 5-in-1 vaccine.

New GSK sign
• Source: Shutterstock

Pfizer was the first to launch a 5-in-1 meningococcal vaccine, Penbraya, two years ago but failed to capitalize on its advantage, and now rival GSK looks set to confirm its dominance in the field with its new product, Penmenvy.

The 5-in-1 vaccine was approved on 14 February by the US Food and Drug Administration for use in individuals aged...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Therapy Areas

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.